Literature DB >> 15663212

Mast cells and canine mast cell tumours. A review.

W Misdorp1.   

Abstract

This article reviews the literature on mast cells and tumours derived from mast cells in the dog. Mast cells play a central role in inflammatory and immune reactions. Mast cells, normal and neoplastic, contain and release important biologically active substances: heparin, histamine, eosinophilic chemotactic factor and proteolytic enzymes. Mast cell tumours occur in the dog, particularly in the boxer and related breeds, in the skin and less frequently in the intestines. Cytology usually provides an accurate diagnosis, but histological examination adds further information concerning the histologic grade and the completeness of surgical therapy. Cutaneous mast cell tumours should be regarded as potentially malignant and therefore be removed widely (3 cm. margin). Local recurrence, regional and distant metastases together with paraneoplastic disorders may cause the death of the pet. Histologic grading (2 or 3 grades) and clinical staging together with kinetic parameters and breed (boxers have relatively benign tumours) are important prognostic parameters. Based on prognostic criteria, surgical treatment should be completed with adjuvant radiotherapy, corticosteroids and eventually with combined chemotherapy. A novel, promising therapy is the application of the receptor kinase inhibitor. The study of the pathogenesis of mast cell tumours received new impetus by the finding of mutations, deletions and duplications, in exons 11 and 12 of the C-kit oncogene. Further study of physiological and oncological aspects of mast cells are favoured by the availability of mast cells isolated from spontaneous mast cell tumours and of cultured cell lines.

Entities:  

Mesh:

Year:  2004        PMID: 15663212     DOI: 10.1080/01652176.2004.9695178

Source DB:  PubMed          Journal:  Vet Q        ISSN: 0165-2176            Impact factor:   3.320


  20 in total

1.  The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors.

Authors:  Joshua D Webster; Vilma Yuzbasiyan-Gurkan; John B Kaneene; RoseAnn Miller; James H Resau; Matti Kiupel
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

2.  The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

Authors:  Alexandra Keller; Bettina Wingelhofer; Barbara Peter; Karin Bauer; Daniela Berger; Susanne Gamperl; Martin Reifinger; Sabine Cerny-Reiterer; Richard Moriggl; Michael Willmann; Peter Valent; Emir Hadzijusufovic
Journal:  Vet Comp Oncol       Date:  2017-04-11       Impact factor: 2.613

3.  Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.

Authors:  Joshua D Webster; Matti Kiupel; Vilma Yuzbasiyan-Gurkan
Journal:  BMC Cancer       Date:  2006-04-01       Impact factor: 4.430

4.  Prevalence and risk factors for mast cell tumours in dogs in England.

Authors:  Stephanie Jw Shoop; Stephanie Marlow; David B Church; Kate English; Paul D McGreevy; Anneliese J Stell; Peter C Thomson; Dan G O'Neill; David C Brodbelt
Journal:  Canine Genet Epidemiol       Date:  2015-01-26

5.  The Effect of Co0.2Mn0.8Fe2O4 Ferrite Nanoparticles on the C2 Canine Mastocytoma Cell Line and Adipose-Derived Mesenchymal Stromal Stem Cells (ASCs) Cultured Under a Static Magnetic Field: Possible Implications in the Treatment of Dog Mastocytoma.

Authors:  K Marycz; M Marędziak; D Lewandowski; E Zachanowicz; A Zięcina; R J Wiglusz; R Pązik
Journal:  Cell Mol Bioeng       Date:  2017-02-21       Impact factor: 2.321

6.  Malignant mast cell tumor of the thymus in an Royal College of Surgeons (RCS) rat.

Authors:  Yui Terayama; Tetsuro Matsuura; Kiyokazu Ozaki
Journal:  J Toxicol Pathol       Date:  2016-10-10       Impact factor: 1.628

7.  Electrochemotherapy Effectiveness Loss due to Electric Field Indentation between Needle Electrodes: A Numerical Study.

Authors:  José Alvim Berkenbrock; Rafaela Grecco Machado; Daniela Ota Hisayasu Suzuki
Journal:  J Healthc Eng       Date:  2018-07-02       Impact factor: 2.682

8.  Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.

Authors:  Joshua D Webster; Vilma Yuzbasiyan-Gurkan; Douglas H Thamm; Elizabeth Hamilton; Matti Kiupel
Journal:  BMC Vet Res       Date:  2008-08-13       Impact factor: 2.741

9.  Cutaneous mast cell tumor (Mastocytoma): cyto- histopathological and haematological investigations.

Authors:  Ehsan Hosseini; Behnam Pedram; Ali Mohammad Bahrami; Mohammad Hossein Jaberi Moghaddam; Javad Javanbakht; Fatemeh Emami Ghomi; Najme Jaberi Moghaddam; Mobin Koohestani; Radmehr Shafiee
Journal:  Diagn Pathol       Date:  2014-01-20       Impact factor: 2.644

10.  Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report.

Authors:  Faizan Malik; Naveed Ali; Syed Imran Mustafa Jafri; Ali Ghani; Mohsin Hamid; Margot Boigon; Christian Fidler
Journal:  J Med Case Rep       Date:  2017-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.